PURPOSE: The monohydroxylated metabolite of arachidonic acid, 20-hydroxyeicosatetraenoic acid (20-HETE), is a potent vasoconstrictor of cerebral microvessels. 20-HETE formation is substantially elevated in the cerebral spinal fluid (CSF) in the rat subarachnoid hemorrhage (SAH) model. The presence of 20-HETE in human CSF has not been demonstrated. Therefore, it was the purpose of this study to determine if HETE metabolites are present in human CSF after SAH. METHODS: CSF samples were collected daily from four SAH patients over 15 days. HETE metabolites were separated by HPLC with identification by ion-trap MS/MS and quantification via single quadrupole MS operating in negative single ion monitoring mode. RESULTS: Two major metabolites were identified as 12-HETE and 20-HETE. 20-HETE maximal concentrations were 2.9 and 0.7 ng/ml at approximately 70 h in the two patients with symptomatic cerebral vasospasm (SV) after SAH. Concentrations of 12-HETE in these patients peaked at 21.9 ng/ml and 2.8 ng/ml. Concentrations of 20-HETE and 12-HETE were non-detectible in the majority of the samples obtained from two matched SAH patients without SV. CONCLUSIONS: This study is the first to demonstrate that 20-HETE and 12-HETE are present in the CSF of SAH patients at physiologically relevant concentrations. Based on this information future prospective studies will allow for the delineation of the role of these metabolites in the pathogenesis of SAH.
PURPOSE: The monohydroxylated metabolite of arachidonic acid, 20-hydroxyeicosatetraenoic acid (20-HETE), is a potent vasoconstrictor of cerebral microvessels. 20-HETE formation is substantially elevated in the cerebral spinal fluid (CSF) in the ratsubarachnoid hemorrhage (SAH) model. The presence of 20-HETE in human CSF has not been demonstrated. Therefore, it was the purpose of this study to determine if HETE metabolites are present in human CSF after SAH. METHODS: CSF samples were collected daily from four SAHpatients over 15 days. HETE metabolites were separated by HPLC with identification by ion-trap MS/MS and quantification via single quadrupole MS operating in negative single ion monitoring mode. RESULTS: Two major metabolites were identified as 12-HETE and 20-HETE. 20-HETE maximal concentrations were 2.9 and 0.7 ng/ml at approximately 70 h in the two patients with symptomatic cerebral vasospasm (SV) after SAH. Concentrations of 12-HETE in these patients peaked at 21.9 ng/ml and 2.8 ng/ml. Concentrations of 20-HETE and 12-HETE were non-detectible in the majority of the samples obtained from two matched SAHpatients without SV. CONCLUSIONS: This study is the first to demonstrate that 20-HETE and 12-HETE are present in the CSF of SAHpatients at physiologically relevant concentrations. Based on this information future prospective studies will allow for the delineation of the role of these metabolites in the pathogenesis of SAH.
Authors: Elizabeth A Crago; Bhavani P Thampatty; Paula R Sherwood; Chie-Wen J Kuo; Catherine Bender; Jeffrey Balzer; Michael Horowitz; Samuel M Poloyac Journal: Stroke Date: 2011-05-26 Impact factor: 7.914
Authors: Rosanne Salonia; Philip E Empey; Samuel M Poloyac; Stephen R Wisniewski; Megan Klamerus; Haishin Ozawa; Amy K Wagner; Randall Ruppel; Michael J Bell; Keri Feldman; P David Adelson; Robert S B Clark; Patrick M Kochanek Journal: J Neurotrauma Date: 2010-09-17 Impact factor: 5.269
Authors: Hülya Bayır; Tamil S Anthonymuthu; Yulia Y Tyurina; Sarju J Patel; Andrew A Amoscato; Andrew M Lamade; Qin Yang; Georgy K Vladimirov; Caroline C Philpott; Valerian E Kagan Journal: Cell Chem Biol Date: 2020-04-09 Impact factor: 8.116
Authors: Mark K Donnelly; Elizabeth A Crago; Yvette P Conley; Jeffery R Balzer; Dianxu Ren; Andrew F Ducruet; Patrick M Kochanek; Paula R Sherwood; Samuel M Poloyac Journal: J Cereb Blood Flow Metab Date: 2015-04-29 Impact factor: 6.200
Authors: Dominic A Siler; Ross P Martini; Jonathan P Ward; Jonathan W Nelson; Rohan N Borkar; Kristen L Zuloaga; Jesse J Liu; Stacy L Fairbanks; Jeffrey S Raskin; Valerie C Anderson; Aclan Dogan; Ruikang K Wang; Nabil J Alkayed; Justin S Cetas Journal: Neurocrit Care Date: 2015-04 Impact factor: 3.210
Authors: Mark K Donnelly; Yvette P Conley; Elizabeth A Crago; Dianxu Ren; Paula R Sherwood; Jeffery R Balzer; Samuel M Poloyac Journal: J Cereb Blood Flow Metab Date: 2014-11-12 Impact factor: 6.200
Authors: Debebe Gebremedhin; David X Zhang; Koryn A Carver; Nicole Rau; Kevin R Rarick; Richard J Roman; David R Harder Journal: Prostaglandins Other Lipid Mediat Date: 2016-05-09 Impact factor: 3.072
Authors: Tricia M Miller; Mark K Donnelly; Elizabeth A Crago; Dana M Roman; Paula R Sherwood; Michael B Horowitz; Samuel M Poloyac Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2009-10-14 Impact factor: 3.205